NORTHWEST BIOTHERAPEUTICS INC (NWBO)
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Northwest Biotherapeutics, Inc.
- 3.9%
- 69.4M
- 7.78
Float 1.78B · Signal8 dilution snapshot · Nov 13, 2026
The cost to borrow NWBO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 57.8%
- 21.1K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 69.4M sh |
| Oct 15, 2026 | 73.1M sh |
| Sep 30, 2026 | 76.8M sh |
| Sep 15, 2026 | 75.5M sh |
| Aug 31, 2026 | 70.3M sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 29, 2026 | 21.1K sh |
| Oct 27, 2026 | 969.9K sh |
| Oct 23, 2026 | 300.5K sh |
| Oct 21, 2026 | 1.2M sh |
| Oct 20, 2026 | 271.5K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 57.8% |
| Nov 13, 2026 | 49.4% |
| Nov 12, 2026 | 66.4% |
| Nov 11, 2026 | 48.6% |
| Nov 10, 2026 | 55.0% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for NWBO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 69,421,915 NWBO shares were sold short (3.91% of a 1.78B-share float, 7.78 days to cover).